Loading…
Clinical values of multiple Epstein-Barr virus (EBV) serological biomarkers detected by xMAP technology
Serological examination of Epstein-Barr virus (EBV) antibodies has been performed for screening nasopharyngeal carcinoma (NPC) and other EBV-associated diseases. By using xMAP technology, we examined immunoglobulin (Ig) A antibodies against Epstein-Barr virus (EBV) VCA-gp125, p18 and IgA/IgG against...
Saved in:
| Published in: | Journal of translational medicine 2009-08, Vol.7 (1), p.73-73, Article 73 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-b612t-320d7ce08737bcc4b56824957aae42fe3dff1bfa41c5578c35be6cef09167c3a3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-b612t-320d7ce08737bcc4b56824957aae42fe3dff1bfa41c5578c35be6cef09167c3a3 |
| container_end_page | 73 |
| container_issue | 1 |
| container_start_page | 73 |
| container_title | Journal of translational medicine |
| container_volume | 7 |
| creator | Gu, Ai-Di Lu, Li-Xia Xie, Yan-Bo Chen, Li-Zhen Feng, Qi-Sheng Kang, Tiebang Jia, Wei-Hua Zeng, Yi-Xin |
| description | Serological examination of Epstein-Barr virus (EBV) antibodies has been performed for screening nasopharyngeal carcinoma (NPC) and other EBV-associated diseases.
By using xMAP technology, we examined immunoglobulin (Ig) A antibodies against Epstein-Barr virus (EBV) VCA-gp125, p18 and IgA/IgG against EA-D, EBNA1 and gp78 in populations with distinct diseases, or with different genetic or geographic background. Sera from Cantonese NPC patients (n = 547) and healthy controls (n = 542), 90 members of high-risk NPC families and 52 non-endemic healthy individuals were tested. Thirty-five of NPC patients were recruited to observe the kinetics of EBV antibody levels during and after treatment. Patients with other EBV-associated diseases were collected, including 16 with infectious mononucleosis, 28 with nasal NK/T cell lymphoma and 14 with Hodgkin's disease.
Both the sensitivity and specificity of each marker for NPC diagnosis ranged 61-84%, but if combined, they could reach to 84.5% and 92.4%, respectively. Almost half of NPC patients displayed decreased EBV immunoactivities shortly after therapy and tumor recurrence was accompanied with high EBV antibody reactivates. Neither the unaffected members from high-risk NPC families nor non-endemic healthy population showed statistically different EBV antibody levels compared with endemic controls. Moreover, elevated levels of specific antibodies were observed in other EBV-associated diseases, but all were lower than those in NPC.
Combined EBV serological biomarkers could improve the diagnostic values for NPC. Diverse EBV serological spectrums presented in populations with different EBV-associated diseases, but NPC patients have the highest EBV activity. |
| doi_str_mv | 10.1186/1479-5876-7-73 |
| format | article |
| fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_70ebadbe949d46848390e159679bcbc1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A206868390</galeid><doaj_id>oai_doaj_org_article_70ebadbe949d46848390e159679bcbc1</doaj_id><sourcerecordid>A206868390</sourcerecordid><originalsourceid>FETCH-LOGICAL-b612t-320d7ce08737bcc4b56824957aae42fe3dff1bfa41c5578c35be6cef09167c3a3</originalsourceid><addsrcrecordid>eNp9UsFu1DAQjRCIlsKVI7KEhMohJY4dO74gbVdbqFQEB-Bq2c5k68WJt3ayYv--TnfVdgEhH2zPvHl-88ZZ9hoXZxjX7AOmXORVzVnOc06eZMf3gaePzkfZixhXRVHSiorn2REWTNSYlcfZcu5sb41yaKPcCBH5FnWjG-zaAVqs4wC2z89VCGhjwxjR6eL853sUIXjnl3d12vpOhV8QImpgADNAg_QW_f4y-4bS9bqfkNuX2bNWuQiv9vtJ9uNi8X3-Ob_6-ulyPrvKNcPlkJOyaLiBouaEa2OorlhdUlFxpYCWLZCmbbFuFcWmqnhtSKWBGWgLgRk3RJGT7HLH23i1kutgk7at9MrKu4APS6nCYI0DyQvQqtEgqGgoq2lNRAG4EowLbbTBievjjms96g4aA_0QlDsgPcz09lou_UaWnFBe8UQw2xFMHv2b4DBjfCenoclpaJJLThLHu72I4G_SgAbZ2WjAOdWDH6NknJUFE5Pa0_8CMWGc1gxXZYK-_QO68mPo01wSitacYkppQp3tUEuV3LJ965NGk1YDnTW-h9am-Cy9XrPJu4cCE3yMAdr7TnEhp9_6d29vHhv8AN9_T3ILcAfl-w</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1348741444</pqid></control><display><type>article</type><title>Clinical values of multiple Epstein-Barr virus (EBV) serological biomarkers detected by xMAP technology</title><source>Publicly Available Content (ProQuest)</source><source>PubMed Central</source><creator>Gu, Ai-Di ; Lu, Li-Xia ; Xie, Yan-Bo ; Chen, Li-Zhen ; Feng, Qi-Sheng ; Kang, Tiebang ; Jia, Wei-Hua ; Zeng, Yi-Xin</creator><creatorcontrib>Gu, Ai-Di ; Lu, Li-Xia ; Xie, Yan-Bo ; Chen, Li-Zhen ; Feng, Qi-Sheng ; Kang, Tiebang ; Jia, Wei-Hua ; Zeng, Yi-Xin</creatorcontrib><description>Serological examination of Epstein-Barr virus (EBV) antibodies has been performed for screening nasopharyngeal carcinoma (NPC) and other EBV-associated diseases.
By using xMAP technology, we examined immunoglobulin (Ig) A antibodies against Epstein-Barr virus (EBV) VCA-gp125, p18 and IgA/IgG against EA-D, EBNA1 and gp78 in populations with distinct diseases, or with different genetic or geographic background. Sera from Cantonese NPC patients (n = 547) and healthy controls (n = 542), 90 members of high-risk NPC families and 52 non-endemic healthy individuals were tested. Thirty-five of NPC patients were recruited to observe the kinetics of EBV antibody levels during and after treatment. Patients with other EBV-associated diseases were collected, including 16 with infectious mononucleosis, 28 with nasal NK/T cell lymphoma and 14 with Hodgkin's disease.
Both the sensitivity and specificity of each marker for NPC diagnosis ranged 61-84%, but if combined, they could reach to 84.5% and 92.4%, respectively. Almost half of NPC patients displayed decreased EBV immunoactivities shortly after therapy and tumor recurrence was accompanied with high EBV antibody reactivates. Neither the unaffected members from high-risk NPC families nor non-endemic healthy population showed statistically different EBV antibody levels compared with endemic controls. Moreover, elevated levels of specific antibodies were observed in other EBV-associated diseases, but all were lower than those in NPC.
Combined EBV serological biomarkers could improve the diagnostic values for NPC. Diverse EBV serological spectrums presented in populations with different EBV-associated diseases, but NPC patients have the highest EBV activity.</description><identifier>ISSN: 1479-5876</identifier><identifier>EISSN: 1479-5876</identifier><identifier>DOI: 10.1186/1479-5876-7-73</identifier><identifier>PMID: 19698162</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Adult ; Antibodies, Viral - blood ; Asian Continental Ancestry Group ; Biological markers ; Biomarkers ; Biomarkers - metabolism ; Cancer ; Child ; China ; Diagnosis ; Disease ; Drug therapy ; Epstein-Barr virus ; Epstein-Barr Virus Infections - blood ; Epstein-Barr Virus Infections - immunology ; Health aspects ; Herpesvirus 4, Human - immunology ; Humans ; Immunoglobulin A - blood ; Immunoglobulin A - immunology ; Infections ; Lymphoma ; Medical research ; Middle Aged ; Nasopharyngeal cancer ; Nasopharyngeal Neoplasms - diagnosis ; Nasopharyngeal Neoplasms - immunology ; Peptides ; Peptides - genetics ; Peptides - metabolism ; Risk Factors ; Sensitivity and Specificity ; Viral Proteins - immunology</subject><ispartof>Journal of translational medicine, 2009-08, Vol.7 (1), p.73-73, Article 73</ispartof><rights>COPYRIGHT 2009 BioMed Central Ltd.</rights><rights>2009 Gu et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</rights><rights>Copyright © 2009 Gu et al; licensee BioMed Central Ltd. 2009 Gu et al; licensee BioMed Central Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b612t-320d7ce08737bcc4b56824957aae42fe3dff1bfa41c5578c35be6cef09167c3a3</citedby><cites>FETCH-LOGICAL-b612t-320d7ce08737bcc4b56824957aae42fe3dff1bfa41c5578c35be6cef09167c3a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2734757/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1348741444?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19698162$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gu, Ai-Di</creatorcontrib><creatorcontrib>Lu, Li-Xia</creatorcontrib><creatorcontrib>Xie, Yan-Bo</creatorcontrib><creatorcontrib>Chen, Li-Zhen</creatorcontrib><creatorcontrib>Feng, Qi-Sheng</creatorcontrib><creatorcontrib>Kang, Tiebang</creatorcontrib><creatorcontrib>Jia, Wei-Hua</creatorcontrib><creatorcontrib>Zeng, Yi-Xin</creatorcontrib><title>Clinical values of multiple Epstein-Barr virus (EBV) serological biomarkers detected by xMAP technology</title><title>Journal of translational medicine</title><addtitle>J Transl Med</addtitle><description>Serological examination of Epstein-Barr virus (EBV) antibodies has been performed for screening nasopharyngeal carcinoma (NPC) and other EBV-associated diseases.
By using xMAP technology, we examined immunoglobulin (Ig) A antibodies against Epstein-Barr virus (EBV) VCA-gp125, p18 and IgA/IgG against EA-D, EBNA1 and gp78 in populations with distinct diseases, or with different genetic or geographic background. Sera from Cantonese NPC patients (n = 547) and healthy controls (n = 542), 90 members of high-risk NPC families and 52 non-endemic healthy individuals were tested. Thirty-five of NPC patients were recruited to observe the kinetics of EBV antibody levels during and after treatment. Patients with other EBV-associated diseases were collected, including 16 with infectious mononucleosis, 28 with nasal NK/T cell lymphoma and 14 with Hodgkin's disease.
Both the sensitivity and specificity of each marker for NPC diagnosis ranged 61-84%, but if combined, they could reach to 84.5% and 92.4%, respectively. Almost half of NPC patients displayed decreased EBV immunoactivities shortly after therapy and tumor recurrence was accompanied with high EBV antibody reactivates. Neither the unaffected members from high-risk NPC families nor non-endemic healthy population showed statistically different EBV antibody levels compared with endemic controls. Moreover, elevated levels of specific antibodies were observed in other EBV-associated diseases, but all were lower than those in NPC.
Combined EBV serological biomarkers could improve the diagnostic values for NPC. Diverse EBV serological spectrums presented in populations with different EBV-associated diseases, but NPC patients have the highest EBV activity.</description><subject>Adult</subject><subject>Antibodies, Viral - blood</subject><subject>Asian Continental Ancestry Group</subject><subject>Biological markers</subject><subject>Biomarkers</subject><subject>Biomarkers - metabolism</subject><subject>Cancer</subject><subject>Child</subject><subject>China</subject><subject>Diagnosis</subject><subject>Disease</subject><subject>Drug therapy</subject><subject>Epstein-Barr virus</subject><subject>Epstein-Barr Virus Infections - blood</subject><subject>Epstein-Barr Virus Infections - immunology</subject><subject>Health aspects</subject><subject>Herpesvirus 4, Human - immunology</subject><subject>Humans</subject><subject>Immunoglobulin A - blood</subject><subject>Immunoglobulin A - immunology</subject><subject>Infections</subject><subject>Lymphoma</subject><subject>Medical research</subject><subject>Middle Aged</subject><subject>Nasopharyngeal cancer</subject><subject>Nasopharyngeal Neoplasms - diagnosis</subject><subject>Nasopharyngeal Neoplasms - immunology</subject><subject>Peptides</subject><subject>Peptides - genetics</subject><subject>Peptides - metabolism</subject><subject>Risk Factors</subject><subject>Sensitivity and Specificity</subject><subject>Viral Proteins - immunology</subject><issn>1479-5876</issn><issn>1479-5876</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp9UsFu1DAQjRCIlsKVI7KEhMohJY4dO74gbVdbqFQEB-Bq2c5k68WJt3ayYv--TnfVdgEhH2zPvHl-88ZZ9hoXZxjX7AOmXORVzVnOc06eZMf3gaePzkfZixhXRVHSiorn2REWTNSYlcfZcu5sb41yaKPcCBH5FnWjG-zaAVqs4wC2z89VCGhjwxjR6eL853sUIXjnl3d12vpOhV8QImpgADNAg_QW_f4y-4bS9bqfkNuX2bNWuQiv9vtJ9uNi8X3-Ob_6-ulyPrvKNcPlkJOyaLiBouaEa2OorlhdUlFxpYCWLZCmbbFuFcWmqnhtSKWBGWgLgRk3RJGT7HLH23i1kutgk7at9MrKu4APS6nCYI0DyQvQqtEgqGgoq2lNRAG4EowLbbTBievjjms96g4aA_0QlDsgPcz09lou_UaWnFBe8UQw2xFMHv2b4DBjfCenoclpaJJLThLHu72I4G_SgAbZ2WjAOdWDH6NknJUFE5Pa0_8CMWGc1gxXZYK-_QO68mPo01wSitacYkppQp3tUEuV3LJ965NGk1YDnTW-h9am-Cy9XrPJu4cCE3yMAdr7TnEhp9_6d29vHhv8AN9_T3ILcAfl-w</recordid><startdate>20090823</startdate><enddate>20090823</enddate><creator>Gu, Ai-Di</creator><creator>Lu, Li-Xia</creator><creator>Xie, Yan-Bo</creator><creator>Chen, Li-Zhen</creator><creator>Feng, Qi-Sheng</creator><creator>Kang, Tiebang</creator><creator>Jia, Wei-Hua</creator><creator>Zeng, Yi-Xin</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7U9</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20090823</creationdate><title>Clinical values of multiple Epstein-Barr virus (EBV) serological biomarkers detected by xMAP technology</title><author>Gu, Ai-Di ; Lu, Li-Xia ; Xie, Yan-Bo ; Chen, Li-Zhen ; Feng, Qi-Sheng ; Kang, Tiebang ; Jia, Wei-Hua ; Zeng, Yi-Xin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b612t-320d7ce08737bcc4b56824957aae42fe3dff1bfa41c5578c35be6cef09167c3a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adult</topic><topic>Antibodies, Viral - blood</topic><topic>Asian Continental Ancestry Group</topic><topic>Biological markers</topic><topic>Biomarkers</topic><topic>Biomarkers - metabolism</topic><topic>Cancer</topic><topic>Child</topic><topic>China</topic><topic>Diagnosis</topic><topic>Disease</topic><topic>Drug therapy</topic><topic>Epstein-Barr virus</topic><topic>Epstein-Barr Virus Infections - blood</topic><topic>Epstein-Barr Virus Infections - immunology</topic><topic>Health aspects</topic><topic>Herpesvirus 4, Human - immunology</topic><topic>Humans</topic><topic>Immunoglobulin A - blood</topic><topic>Immunoglobulin A - immunology</topic><topic>Infections</topic><topic>Lymphoma</topic><topic>Medical research</topic><topic>Middle Aged</topic><topic>Nasopharyngeal cancer</topic><topic>Nasopharyngeal Neoplasms - diagnosis</topic><topic>Nasopharyngeal Neoplasms - immunology</topic><topic>Peptides</topic><topic>Peptides - genetics</topic><topic>Peptides - metabolism</topic><topic>Risk Factors</topic><topic>Sensitivity and Specificity</topic><topic>Viral Proteins - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gu, Ai-Di</creatorcontrib><creatorcontrib>Lu, Li-Xia</creatorcontrib><creatorcontrib>Xie, Yan-Bo</creatorcontrib><creatorcontrib>Chen, Li-Zhen</creatorcontrib><creatorcontrib>Feng, Qi-Sheng</creatorcontrib><creatorcontrib>Kang, Tiebang</creatorcontrib><creatorcontrib>Jia, Wei-Hua</creatorcontrib><creatorcontrib>Zeng, Yi-Xin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Virology and AIDS Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Journal of translational medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gu, Ai-Di</au><au>Lu, Li-Xia</au><au>Xie, Yan-Bo</au><au>Chen, Li-Zhen</au><au>Feng, Qi-Sheng</au><au>Kang, Tiebang</au><au>Jia, Wei-Hua</au><au>Zeng, Yi-Xin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical values of multiple Epstein-Barr virus (EBV) serological biomarkers detected by xMAP technology</atitle><jtitle>Journal of translational medicine</jtitle><addtitle>J Transl Med</addtitle><date>2009-08-23</date><risdate>2009</risdate><volume>7</volume><issue>1</issue><spage>73</spage><epage>73</epage><pages>73-73</pages><artnum>73</artnum><issn>1479-5876</issn><eissn>1479-5876</eissn><abstract>Serological examination of Epstein-Barr virus (EBV) antibodies has been performed for screening nasopharyngeal carcinoma (NPC) and other EBV-associated diseases.
By using xMAP technology, we examined immunoglobulin (Ig) A antibodies against Epstein-Barr virus (EBV) VCA-gp125, p18 and IgA/IgG against EA-D, EBNA1 and gp78 in populations with distinct diseases, or with different genetic or geographic background. Sera from Cantonese NPC patients (n = 547) and healthy controls (n = 542), 90 members of high-risk NPC families and 52 non-endemic healthy individuals were tested. Thirty-five of NPC patients were recruited to observe the kinetics of EBV antibody levels during and after treatment. Patients with other EBV-associated diseases were collected, including 16 with infectious mononucleosis, 28 with nasal NK/T cell lymphoma and 14 with Hodgkin's disease.
Both the sensitivity and specificity of each marker for NPC diagnosis ranged 61-84%, but if combined, they could reach to 84.5% and 92.4%, respectively. Almost half of NPC patients displayed decreased EBV immunoactivities shortly after therapy and tumor recurrence was accompanied with high EBV antibody reactivates. Neither the unaffected members from high-risk NPC families nor non-endemic healthy population showed statistically different EBV antibody levels compared with endemic controls. Moreover, elevated levels of specific antibodies were observed in other EBV-associated diseases, but all were lower than those in NPC.
Combined EBV serological biomarkers could improve the diagnostic values for NPC. Diverse EBV serological spectrums presented in populations with different EBV-associated diseases, but NPC patients have the highest EBV activity.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>19698162</pmid><doi>10.1186/1479-5876-7-73</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1479-5876 |
| ispartof | Journal of translational medicine, 2009-08, Vol.7 (1), p.73-73, Article 73 |
| issn | 1479-5876 1479-5876 |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_70ebadbe949d46848390e159679bcbc1 |
| source | Publicly Available Content (ProQuest); PubMed Central |
| subjects | Adult Antibodies, Viral - blood Asian Continental Ancestry Group Biological markers Biomarkers Biomarkers - metabolism Cancer Child China Diagnosis Disease Drug therapy Epstein-Barr virus Epstein-Barr Virus Infections - blood Epstein-Barr Virus Infections - immunology Health aspects Herpesvirus 4, Human - immunology Humans Immunoglobulin A - blood Immunoglobulin A - immunology Infections Lymphoma Medical research Middle Aged Nasopharyngeal cancer Nasopharyngeal Neoplasms - diagnosis Nasopharyngeal Neoplasms - immunology Peptides Peptides - genetics Peptides - metabolism Risk Factors Sensitivity and Specificity Viral Proteins - immunology |
| title | Clinical values of multiple Epstein-Barr virus (EBV) serological biomarkers detected by xMAP technology |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T18%3A05%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20values%20of%20multiple%20Epstein-Barr%20virus%20(EBV)%20serological%20biomarkers%20detected%20by%20xMAP%20technology&rft.jtitle=Journal%20of%20translational%20medicine&rft.au=Gu,%20Ai-Di&rft.date=2009-08-23&rft.volume=7&rft.issue=1&rft.spage=73&rft.epage=73&rft.pages=73-73&rft.artnum=73&rft.issn=1479-5876&rft.eissn=1479-5876&rft_id=info:doi/10.1186/1479-5876-7-73&rft_dat=%3Cgale_doaj_%3EA206868390%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b612t-320d7ce08737bcc4b56824957aae42fe3dff1bfa41c5578c35be6cef09167c3a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1348741444&rft_id=info:pmid/19698162&rft_galeid=A206868390&rfr_iscdi=true |